|
|
|
|
Genetix Pharmaceuticals raises $35 Million in Series B financing
Bangalore: The Cambridge-based developer of gene therapies, Genetix Pharmaceuticals, has raised a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures, along with the participation of TVM Capital, Forbion and Easton Capital...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
Company Focused On Advancing Breakthrough Clinical Programs in Gene Therapy CAMBRIDGE, Mass.--(HSMN NewsFeed)--Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has...
Healthcare Sales & Marketing Network:
Mar 13 2010 5:31PM
Matching: adrenoleukodystrophy
|
Find similar documents
|
|
|
|
Genetix Pharmaceuticals, Inc. Secures $
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock...
|
|
|
Genetix raises $35M venture round
Genetix Pharmaceuticals Inc.has raised a venture round of $35 million dollars following the release of data showing that its drug target for a rare disease called Adrenoleukodystrophy (ALD) has halted the ailment in three human cases. The genetic...
|
|
|
Genetix raises $35m to deliver gene therapy
Genetix Pharmaceuticals has completed a $35m series B financing, with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital.Genetixs products treat the underlying cause of genetically based diseases by...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
BusinessWire - Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
CAMBRIDGE, Mass.- (BUSINESS WIRE) - Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
CAMBRIDGE, Mass.Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
CAMBRIDGE, Mass.Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
CAMBRIDGE, Mass.- (Business Wire) Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
CAMBRIDGE, Mass.- (Business Wire) Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
Company Focused On Advancing Breakthrough Clinical Programs in Gene Therapy CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 12, 2010 - Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced...
|
|
|
Genetix raises $35M to advance gene therapies
Cambridge, MA-based Genetix Pharmaceuticals has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital.The company was founded in 1993, but in 2004 Genetix was re...
|
|
|
Genetix raises $35M venture round
has raised a venture round of $35 million dollars following the release of data showing that its drug target for a rare disease called Adrenoleukodystrophy (ALD) has halted the ailment in three human cases.The genetic disease was featured in the movie...
|
|
|
Genetix Raises $35 million
Genetix Pharmaceuticals, a gene therapy company developing treatments for severe genetic disorders, completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital.Press...
|
|
|
Genetix raises $35M venture round
Genetix Pharmaceuticals Inc.has raised a venture round of $35 million dollars following the release of data showing that its drug target for a rare disease called Adrenoleukodystrophy (ALD) has halted the ailment in three human cases. The genetic...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
Company Focused On Advancing Breakthrough Clinical Programs in Gene Therapy CAMBRIDGE, Mass.Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
Company Focused On Advancing Breakthrough Clinical Programs in Gene Therapy CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has...
|
|
|
Genetix Pharmaceuticals announces completion of $35M Series B financing
Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
Company Focused On Advancing Breakthrough Clinical Programs in Gene Therapy CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
Companies mentioned in this article: Genetix Pharmaceuticals CAMBRIDGE, Mass.-- (BUSINESS WIRE) -- Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
Company Focused On Advancing Breakthrough Clinical Programs in Gene Therapy Buzz up!CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today...
|
|
|
Genetix Pharmaceuticals Secures $35M in Series B Funding
Company Focused On Advancing Breakthrough Clinical Programs in Gene Therapy CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has...
|
